Literature DB >> 10348773

Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans.

E J Goldstein1, D M Citron, C V Merriam.   

Abstract

Linezolid was tested against 420 aerobes and anaerobes, including 148 Pasteurella isolates, by an agar dilution method. Linezolid was active against all Pasteurella multocida subsp. multocida and P. multocida subsp. septica isolates and most Pasteurella canis, Pasteurella dagmatis, and Pasteurella stomatis isolates. The MIC was </=2 microg/ml for staphylococci, streptococci, EF-4b, Weeksella zoohelcum, Fusobacterium nucleatum, other fusobacteria, Porphyromonas spp., Prevotella spp., peptostreptococci, and almost all Bacteroides tectum isolates.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10348773      PMCID： PMC89299          DOI： 10.1128/AAC.43.6.1469

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans.

Authors:  E J Goldstein; D M Citron; S Hunt Gerardo; M Hudspeth; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.

Authors:  E J Goldstein; D M Citron; M Hudspeth; S Hunt Gerardo; C V Merriam
Journal:  J Antimicrob Chemother       Date:  1998-03       Impact factor: 5.790

3.  In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria.

Authors:  B H Yagi; G E Zurenko
Journal:  Anaerobe       Date:  1997-10       Impact factor: 3.331

4.  Erythromycin failure with subsequent Pasteurella multocida meningitis and septic arthritis in a cat-bite victim.

Authors:  J M Levin; D A Talan
Journal:  Ann Emerg Med       Date:  1990-12       Impact factor: 5.721

Review 5.  Bite wounds and infection.

Authors:  E J Goldstein
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

6.  Characterization of saccharolytic Bacteroides and Prevotella isolates from infected dog and cat bite wounds in humans.

Authors:  C J Alexander; D M Citron; S Hunt Gerardo; M C Claros; D Talan; E J Goldstein
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

7.  In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.

Authors:  J H Jorgensen; M L McElmeel; C W Trippy
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

8.  Bacteriology of human and animal bite wounds.

Authors:  E J Goldstein; D M Citron; B Wield; U Blachman; V L Sutter; T A Miller; S M Finegold
Journal:  J Clin Microbiol       Date:  1978-12       Impact factor: 5.948

9.  Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group.

Authors:  D A Talan; D M Citron; F M Abrahamian; G J Moran; E J Goldstein
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

10.  Characterization and distribution of Pasteurella species recovered from infected humans.

Authors:  E Holst; J Rollof; L Larsson; J P Nielsen
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948
View more
  17 in total

1.  Effect of linezolid in comparison with that of vancomycin on glycocalix production: in vitro study.

Authors:  L Drago; E De Vecchi; M Valli; L Nicola; M R Gismondo
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Authors:  Michael T Sweeney; Gary E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 3.  Linezolid: a review of its use in the management of serious gram-positive infections.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

5.  Fusobacterial infections in children.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

6.  Antimicrobial stewardship and linezolid.

Authors:  Pauline Guillard; Arnaud de La Blanchardière; Vincent Cattoir; Marc-Olivier Fischer; Renaud Verdon; Guillaume Saint-Lorant
Journal:  Int J Clin Pharm       Date:  2014-08-19

7.  Periodontal bacteria in rabbit mandibular and maxillary abscesses.

Authors:  Kerin L Tyrrell; Diane M Citron; Jeffrey R Jenkins; Ellie J C Goldstein
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 8.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

9.  A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?

Authors:  G G Zhanel; C Shroeder; L Vercaigne; A S Gin; J Embil; D J Hoban
Journal:  Can J Infect Dis       Date:  2001-11

10.  Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

Authors:  Brent W Gunderson; Khalid H Ibrahim; Charles A Peloquin; Laurie B Hovde; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.